Vermillion to Report Preliminary Results for Fourth Quarter and Fiscal Year 2011 on February 23, 2012
Management to Hold Investor Conference Call at 4:30 p.m. ET
AUSTIN, Texas, Feb. 6, 2012 /PRNewswire/ --Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focusing on oncology and cardiology, plans to report preliminary results for its fourth quarter and fiscal year 2011 on Thursday, February 23, 2012.
Company management will host a conference call at 4:30 p.m. Eastern time on the same day to discuss results for the periods, which ended December 31, 2011. Select preliminary unaudited results will be issued in a press release prior to the call.
Vermillion's president and chief executive officer, Gail Page, will host the call, followed by a question and answer period.
Date: Thursday, February 23, 2012
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-800-677-8143
Conference ID#: 21576618
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available approximately two hours after the call and until March 8, 2012.
Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay pin number: 21576618
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its well-known scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com.
Liolios Group, Inc.
SOURCE Vermillion, Inc.
More by this Source
Vermillion Reports Third Quarter 2013 Results
Nov 14, 2013, 16:01 ET
American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillion's OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
Nov 12, 2013, 08:31 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.